My own contempt for the more blatant profits-over-patients avarice of Big Pharma aside, this post isn’t about me. It’s about the original pharma bro Martin Shkreli. Shkreli is notorious as the young CEO of Turing Pharmaceuticals who bought the marketing rights to a life-saving antifungal drug for people with AIDS and promptly raised the price from $13.50 to $750 a pill—an increase of 500 percent. He then turned around and bought the one-of-a-kind Wu-Tang Club album Once Upon a Time in Shaolin for $2 million and posted smug Facebook selfies in gangsta poses with crude come-ons to single women who might be looking for a rich, eligible bachelor. He later went to jail for defrauding investors and in 2022 was banned “from directly or indirectly participating in any manner in the pharmaceutical industry.”
While acknowledging that barring Shkreli from pharma might seriously constrain his ability to make a living, the Court determined that his “egregious, deliberate, repetitive, long-running, and ultimately dangerous illegal conduct” warranted banishment for life.
But that didn’t stop Shkreli.
Last Tuesday, the Federal Trade Commission and Attorneys General of seven states asked a federal judge to hold him in contempt, alleging that he flagrantly and repeatedly violated the court order by broadcasting his opinions about drug companies and offering stock-trading tips online.
According to the FTC complaint, shortly after his release from prison in May 2022, Shkreli began livestreaming on YouTube, sharing his Interactive Brokers screen and showing followers how to get rich by shorting pharmaceutical company stocks.
Shorting is a way to profit when a stock’s value declines, rather than increases. The short seller borrows the stock from a brokerage, then sells the borrowed stock, in hopes of repurchasing it at a lower price before returning the stock to the brokerage.
Small drug companies are particularly vulnerable to short selling because their stock price can swing dramatically upon certain events with a binary outcome, such as FDA approval of a product or the success or failure of a clinical drug study.
Shkreli boasted to his online audience that he’d made millions of dollars short-selling pharma stocks, and gloated “I’m the GOAT” at binary events predicting the outcome of clinical drug trials.
Shkreli may be sleazy, but he’s not stupid. Throughout his shady career, he’s always demonstrated a keen ability understand the science behind pharmaceutical drugs and the incremental percentage-point differences in clinical trial data that can determine success or failure.
When the pharma bro speaks, people listen.
According to industry insiders, his online recommendations could exert an “outsized influence” on the market, damaging reputations and sinking share prices in his zeal for short-selling lucre.
The first company on his hit list was Cassava, a small biotech with a drug called simufilam for the treatment of Alzheimer’s disease. For months, Shkreli trashed the company on his livestreams and urged his viewers to: “Stop the bullshit. Short this stock.”
On November 24, 2024, the day before Cassava was set to announce the results of the simulfilam clinical trial, Shkreli declared that if the drug was successful, he would:
1. delete my X account
2. shave my head on YouTube
3. begin estrogen therapy and change my name to Martina
4. move to Haiti
5. retire from business completely
When the drug failed, the total value of his Interactive Brokers account climbed from $138,200 to $841,000.
In 2025, Shkreli focused on shorting three small biotechs: INmune Bio and its potential anti-inflammatory treatment for Alzheimer’s XPro; aTyr, manufacturer of a biologic for interstitial lung disease called efzofitimod; and Capricor, with its lead compound dermamiocel for cardiomyopathy in patients with Duchenne Muscular Dystrophy.
XPro failed, INmune’s stock plummeted, and Shkreli cashed in; efzofitimod failed, aTyr stock fell 80 percent, and Shkreli cashed in; but dermamiocel worked, Capricor’s stock skyrocketed nearly 400 percent, Shkreli lost millions, and cashed out.
According to the FTC filing, in recent livestreams, Shkreli has railed that the Caprocor CEO “fakes this data” and threatened to “send this bitch to jail.”
Temper, temper.
This isn’t the first time the FTC has asked the Federal Court to hold Shkreli in contempt. In a January 2023 filing, the agency accused him of violating the pharmaceutical industry ban by forming and operating a new company, “Druglike, Inc.” that purported to revolutionize early-stage drug discovery through a decentralized computing network. The company has since gone out of business.
For his short-selling shenanigans, the FTC and States Attorneys General are not only asking the Court to hold Shkreli in contempt but to impose a monetary fine in the amount of his profits made through his persistent skullduggery.
Will that stop the pharma bro?
Maybe they should also make him shave his head on YouTube, change his name to Martina, and move to Haiti.


It'd be more intriguing if "Will that stop the pharma bro?" was turned into "Will that stop the pharma sis? after all of the sissis that seem to be around the worm brain eaten.
Like the pimple Internet/AI bros he has no soul. The bright side is that he doesn't have nuclear weapons because the governent owns them. With any luck on his part Trump will replace RFK jr with him.